An important first step in ensuring UHC for RHD will be to invest in supply chains for medications related to RHD, many of which are used for other cardiovascular diseases (e.g., beta-blockers and angiotensin-converting enzyme inhibitors) or for infectious diseases (e.g., benzathine penicillin and azithromycin). This evidence concerns the gene ACE and infectious disease.